Singapore Head and Neck Cancer Therapeutics Market Report 2023 to 2030

Singapore Head and Neck Cancer Therapeutics Market Analysis

$ 3999

The Singapore Head and Neck Cancer Therapeutics Market was valued at $20.74 Mn in 2023 and is predicted to grow at a CAGR of 14% from 2023 to 2030, to $51.90 Mn by 2030. The key drivers of this industry include advancement in treatment, healthcare expenditure, and government initiatives. The industry is primarily dominated by players such as Bristol Myers Squibb, Merck, Pfizer, and AstraZeneca among others.

ID: IN10SGPH577 CATEGORY: Pharmaceuticals GEOGRAPHY: Singapore AUTHOR: Aashwi Mehta

Buy Now

Singapore Head and Neck Cancer Therapeutics Market Executive Summary

The Singapore Head and Neck Cancer Therapeutics Market was valued at $20.74 Mn in 2023 and is predicted to grow at a CAGR of 14% from 2023 to 2030, to $51.90 Mn by 2030.

Head and neck cancer originates from the squamous cells lining the mucosal surfaces of areas like the mouth, throat, and larynx, with potential initial sites including the salivary glands, sinuses, muscles, or nerves in these regions. Common risk factors include alcohol and tobacco use, along with HPV infection. Symptoms may include a painful neck lump, persistent ulcers in the mouth or throat, difficulty swallowing, and a hoarse voice.

In Singapore, nasopharyngeal cancer accounts for 2.1% of new head and neck cancer cases, with a five-year prevalence rate of 2.5 per 100,000 people. The death rate from this cancer type is 2.4%. The market is driven by significant factors like advancement in treatment, healthcare expenditure, and government initiatives. However, the high cost of treatment, regulatory challenges, and limited awareness restrict the growth and potential of the market.

Prominent players in this field include Bristol Myers Squibb, Merck, Pfizer, and AstraZeneca among others.

Singapore Head and Neck Cancer Therapeutics Market Report 2023 to 2030

Market Dynamics

Market Growth Drivers

Advancement in Treatment: The head and neck cancer therapeutics market in Singapore is mostly driven by the integration of cutting-edge technologies, such as immunotherapy and precision medicine, into cancer diagnosis and treatment, which raises consumer demand for these innovative treatments.

Healthcare Expenditure: According to the Ministry of Health, the head and neck cancer therapeutics market in Singapore is significantly driven by the country's projected increase in National Health expenditure to $43 Bn by 2030 and its projected rise in healthcare spending as a percentage of GDP from 5.9% to potentially 9.0%. This forecast indicates a significant financial investment in healthcare and a developing market for medicines and treatments relevant to head and neck cancer.

Government Initiatives: Government initiatives like the establishment and support of the National Cancer Centre Singapore (NCCS), a prominent tertiary cancer center with specialized expertise in cancer treatment, act as significant market drivers for the head and neck cancer therapeutics market in Singapore.

Market Restraints

High Cost of Treatment: For many patients, access to advanced cancer treatments such as immunotherapies and targeted medicines is severely hampered by the high expenses associated with these potentially life-saving measures. The head and neck cancer therapeutics market in Singapore is constrained by this financial burden, which prevents a large number of patients with this illness from adopting and using innovative treatment alternatives.

Regulatory Challenges: Strict regulatory processes and standards for clinical trial and drug approval could lengthen the time needed to introduce novel therapies into the market, hindering innovation and the availability of new treatments. This slows down the introduction and access to novel therapy options for patients in need, which serves as a market restraint for Singapore's head and neck cancer therapeutics market.

Limited awareness: Lack of awareness affects early detection and treatment-seeking behavior, and it serves as a market restraint for Singapore's head and neck cancer therapeutics market. Lack of knowledge causes delayed diagnosis, which makes advanced-stage tumors more difficult to treat successfully. This lowers the overall demand for therapeutic interventions, limiting the development of the market and the timely and effective implementation of treatment plans.

Regulatory Landscape and Reimbursement Scenario

Singapore's Health Sciences Authority (HSA) is the organization in charge of regulating pharmaceutical and healthcare goods. To guarantee that they fulfill the necessary safety, efficacy, and quality criteria, the HSA also regulates pharmaceutical pharmaceuticals, complementary and alternative medicine, medical devices, and other health products. The Cancer Care Fund in Singapore is designed as a one-time financial support program aimed at easing the financial strain experienced by newly diagnosed cancer patients from low or middle-income families during the initial 6 months following diagnosis. MediShield serves as a medical insurance plan intended to assist in covering substantial hospitalization costs. It includes coverage for hospitalization expenses and specific outpatient treatments that are approved, such as chemotherapy and radiotherapy for cancer.

Competitive Landscape

Key Players

Here are some of the major key players in the Singapore Head and Neck Cancer Therapeutic Market:

Bristol Myers Squibb
Merck
Pfizer
AstraZeneca
Novartis
Eli Lilly and Company
GlaxoSmithKline
Sanofi
Roche
Takeda Pharmaceutical Company Limited

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Singapore Head and Neck Cancer Therapeutics Market Segmentation

By Treatment

Targeted Therapy
Immunotherapy
Radiation Therapy
Surgeries

By End Users

Hospitals
Specialty Centers
Ambulatory Surgical Centers

By Distribution Channel

Hospital-based pharmacies
Retail pharmacies
Online pharmacies

By Route of administration

Injectable
Oral

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.